Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. Svicher V, et al. Among authors: di nicuolo g, di perri g, di biagio a, di santo f, di pietro m. New Microbiol. 2012 Jan;35(1):17-25. Epub 2012 Jan 10. New Microbiol. 2012. PMID: 22378549 Free article.
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: di biagio a. Infection. 2007 Dec;35(6):451-6. doi: 10.1007/s15010-007-7120-x. Epub 2007 Nov 21. Infection. 2007. PMID: 18034204 Clinical Trial.
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A. Rosso R, et al. Among authors: di biagio a. Pediatr Infect Dis J. 2008 Jan;27(1):17-21. doi: 10.1097/INF.0b013e31814689be. Pediatr Infect Dis J. 2008. PMID: 18162932 Clinical Trial.
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.
Angeli E, Mainini A, Cargnel A, Uberti-Foppa C, Orani A, Carbone R, Andreoni M, Schiavini M, Giorgi R, Rizzardini G, Gubertini G; ICoS-2 Group. Angeli E, et al. Curr HIV Res. 2009 Jul;7(4):447-55. doi: 10.2174/157016209788680507. Curr HIV Res. 2009. PMID: 19601782 Clinical Trial.
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
428 results